Cell Therapeutics vor Tounaround?
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
Last Update: 1/13/2010 6:03:00 PM
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
SEATTLE, Jan 13, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 3 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors. Each share of Series 3 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 823 shares of common stock at a conversion price of $1.21375 per share of common stock, for a total of approximately 24,690,000 common shares.
In connection with the offering, the investors received warrants to purchase up to 8,640,000 shares of common stock. The warrants have an exercise price of $1.18 per warrant share, for total potential additional proceeds to the Company of approximately $10.2 million upon exercise of the warrants. The warrants are exercisable immediately upon issuance and terminate one year and one day after the date of issuance.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications, and general working capital.
Shares of the Series 3 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters.
somit hat jetzt eine ordentliche konsolidierung statt gefunden. bin gespannt wies weiter geht.
30 mio investiert niemand, wenn er nicht vom invest überzeugt ist. glaub die amis verwechseln das mit dilution.
1. Die Firma geht nicht Pleite
2. Durch einen Investor kann sie nicht übernommen werden Poison Pill
3. Neues Medikament steht n den Startlöchern :)
Keine Kaufempfehlung nur meine Meinung
Interessanter Artikel zu den vorgängen Gestern Nacht....
Link: http://www.thestreet.com/story/10661129/1/...-has-strange-timing.html
HOffe er fällt auf die Nase wie bei DNDN.
Optionen
| Boardmail an "crivit" |
Wertpapier: CTI BioPharma |
Also was ist besser?
Genau einen Investor ins Bott zu holen dem einen Anteil zu geben, jedoch den großen Batzen für sich zu behalten. Besser als komplett geschluckt zu werden. lg
Cell Therapeutics said they were able to raise an additional $30 million in preferred stock and warrants. Each preferred stock is convertible into 823 common shares at a conversion price of $1.21375, and the warrants have an exercise price of $1.18 per share. Cell’s management said the company intends to use the money to pay down debt and for general operating purposes involved with a developmental pharma company.
I read Adam F’s take on their caital raising and I have to disagree with him on some of his points. First thing’s first, I think raising the capital so close to a FDA panel meeting is a double edged sword because you will always have the speculators that will say that the company is raising capital because somehow the company knows the drug won’t pass (this is Adam F’s point of view). Another point of view to take (and this is why I say it is a double edged sword) is that most likely the company doesn’t know if the drug will or will not pass, but they know they need to bolster their financing. Like most pharma companies facing the FDA’s ODAC, Cell probably realizes that the panel is lead by non other than Dr. Pazdur–who has been implicated in insider trading leaks (ImClone) and an entire scandal surrounding his involvement in Provenge not getting approved even when the FDA’s own panel voted for approval– and that with him in charge the entire process is an arbitrary gamble.
Not raising capital before the meeting would be the bigger gamble if the company really needs it. Why? For arguments sake, suppose the drug doesn’t get approved and the FDA asks them to run a follow-up trial? Where would the money come from? The company would be forced to raise capital at a lower share price. In my opinion this was probably the smart move for Cell’s management, from their perspective the name of the game is get the money when you know you can get it. Raising capital later would be a huge gamble and a mistake, if Cell needed the money then raising it now was the right move. Not raising capital now would have been the BIG GAMBLE, because if for some reason the FDA doesn’t like what they see, then the company is screwed. Bianco made the right move, contrary to what Adam F thinks, not raising the capital would have been reckless.
LINK: http://www.gekkowire.com/?p=2197#more-2197
Cell Therapeutics Share Price Estimates Based on Different FDA Outcomes
Link: http://www.gekkowire.com/?p=2217&page=1
Top 5 Small Cap Picks for 2010
In 2009 we had some great calls and some not so great. We finished the year up over 600%! We continue to explore the small cap world looking for the next big thing. The world of small cap is not for everyone because it comes with an undeniable risk. However, if you can afford it, and have the stomach, here are our 5 picks for 2010!
Company: Cell Therapeutics
Symbol: CTIC
Key drug: Pixatrone
Potential market cap: $1.1 billion
Target share price: $13
http://bhmpllc.blogspot.com/2010/01/...-small-cap-picks-for-2010.html
Optionen
| Boardmail an "Menne" |
Wertpapier: CTI BioPharma |
Die heisse Phase ist eingeläutert...